This white paper examines the role of accelerated approval therapies within Medicaid spending for rare diseases and provides context around patient access, healthcare costs, and long-term value. The report highlights why maintaining access to innovative therapies remains critical for rare disease patients and families.
New Name, Same Commitment to Rare Diseases
The EveryLife Foundation for Rare Diseases has become The RARE Foundation! Read more about our new brand and how it unifies our advocacy work on behalf of the rare disease community.
